Since the clinical applicability of this route of administration was questionable and information on THOP1-related sensitivity was still lacking, we further investigated intravenous administration of both CBR-049 and CBR-050 (another lead molecule from CoBioRes) in sarcoma xenografts, all selected based on expression of the main activating enzyme THOP1. This evidence concerns the gene THOP1 and sarcoma.